Table 1.
General characteristics of patients
| No adjuvant therapy (n = 59) | Platinum-based chemotherapy (n = 60) | p value | |
|---|---|---|---|
| Age (years) |
64.14 ± 12.75 |
59.80 ± 9.70 |
0.027 |
| Male |
36 (61.0%) |
37 (61.7%) |
0.546 |
| FEV1 (liters) |
90.10 ± 25.99 |
97.91 ± 25.40 |
0.1 |
| Comorbidity |
38 (64.4%) |
33 (55.0%) |
0.352 |
| Type of operation |
|
|
0.489 |
| Lobectomy |
54 (91.5%) |
56 (93.3%) |
|
| Pneumonectomy |
5 (8.5%) |
4 (6.7%) |
|
| Dissected lymph nodes |
22.88 ± 9.21 |
28.08 ± 13.08 |
0.017 |
| Tumor size (mm) |
28.35 ± 9.74 |
33.80 ± 9.82 |
0.003 |
| Pathology |
|
|
0.295 |
| Adenocarcinoma |
27 (45.8%) |
36 (60.0%) |
|
| Squamous cell carcinoma |
18 (30.5%) |
14 (23.3%) |
|
| Others |
14 (23.7%) |
10 (16.7%) |
|
| Differentiation |
|
|
0.306 |
| Well |
17 (28.8%) |
12 (20.0%) |
|
| Moderate to poor |
37 (62.7%) |
39 (65.0%) |
|
| Not defined |
5 (8.5%) |
9 (15.0%) |
|
| Lymphovascular invasion |
8 (13.6%) |
11 (18.3%) |
0.323 |
| Pleural invasion |
|
|
0.428 |
| pl0 |
34 (57.6%) |
28 (46.7%) |
|
| pl1 |
15 (25.4%) |
17 (28.3%) |
|
| pl2 |
10 (16.9%) |
15 (25.0%) |
|
| Performance status (ECOG) |
|
|
0.004 |
| 0 |
36 (61.0%) |
52 (86.7%) |
|
| 1 |
20 (33.9%) |
8 (13.3%) |
|
| 2 | 3 (5.1%) | 0 |